Global Pituitary Dwarf Treatment Market, By Types (Pituitary Dwarfism Type I, Pituitary Dwarfism Type II, Pituitary Dwarfism Type III, Pituitary Dwarfism Type IV, Others), Treatment (Surgery, Additional Therapy, Drugs, Others), Route of Administration (Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Pituitary Dwarf Treatment Market Analysis and Size
Pituitary dwarfism may vary worldwide, usually from 1:30,000 to 1:1800. The demand for the market is increasing rapidly, primarily because of increasing cases of pituitary dysfunction that leads to deficiency of the growth hormone. In adults, the growth hormone deficiency may lead to decreased energy, depressed mood, extreme fatigue, decreased muscle strength, muscle mass, thin and dry skin, increased adipose tissue, and reduced bone density.
Data Bridge Market Research analyses a growth rate in pituitary dwarf treatment market in the forecast period 2023-2030. The expected CAGR of pituitary dwarf treatment market is tend to be around 14.50% in the mentioned forecast period. The market was valued at USD 4.9 billion in 2022, and it would grow upto USD 14.48 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pituitary Dwarf Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Pituitary Dwarfism Type I, Pituitary Dwarfism Type II, Pituitary Dwarfism Type III, Pituitary Dwarfism Type IV, Others), Treatment (Surgery, Additional Therapy, Drugs, Others), Route of Administration (Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd (Israel), Apotex Inc (Canada), Armata Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), H. Lundbeck A/S (Denmark), Alterity Therapeutics (Australia), Vertex Pharmaceuticals Incorporated (U.S.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Pituitary dwarf is also known as growth hormone deficiency disorder. It is the type of condition wherein pituitary gland does not produce enough growth hormone, resulting in a child's slow growth pattern. Various symptoms include chubby body build, immature appearance, prominent forehead, below-average growth, and underdeveloped bridge of the nose among others. This condition starts emerging in childhood itself and becomes even more prominent when the child reaches puberty. The growth and development of the child slows down or gets delayed.
Pituitary Dwarf Treatment Market Dynamics
Drivers
- Increasing Demands of Diagnostic Tests
There are various diagnostic tests that are boosting the demand of the market. Several imaging tests such as X-rays are used as certain abnormalities of the skull and skeleton can specify the disorder the patient has. Numerous imaging devices may also show delayed maturation of bones, as is the case in growth hormone deficiency. A magnetic resonance imaging (MRI) scan may show abnormalities of the pituitary gland or hypothalamus, both of which play a major role in hormone function.
Opportunities
- Growing Demand of Different Treatment Methods
There are numerous treatment methods that are aiding in boosting the growth of the market. Subcutaneous injections are being provided on a daily basis as the dose of hormone therapy until the child finally reached an appropriate height. In girls, hormones such as estrogen and progesterone are added, on the other hand in boys, testosterone is added. Testosterone must be added very carefully as it can have a huge effect on children. Other drugs can also be used to surge the production of growth hormones. Drugs such as arginine, chlonidine, propranolol, and dopamine can be used efficiently. Other anabolic substances such as nandrolone, oxandrolone and fluoxinesterone, help in the stimulation of protein synthesis. This also increases cartilage and bone growth.
Restraints/Challenges
- Side Effects of Pituitary Dwarf Treatment
The pituitary dwarf treatment is involved with several side effects such as rash and pain at the sight of the injection, transient fever, edema, increased insulin resistance and other such problems. This hampers the market growth.
- Discontinuation of Drug Trials
The drug development for the disease has faced major obstacles as numerous therapies have failed to demonstrate efficacy or were associated with major toxicity. Thus, this hampers the growth of the market.
This pituitary dwarf treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pituitary dwarf treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments:
- In 2021, Biocorp and Merck joined hands in the development and global distribution of a specific version of the Mallya device for applications in the field of HGH.
- In 2020, US FDA approved Novo Nordisk, Inc.’s Sogroya (somapacitan), as the first human growth hormone (HGH) therapy that adult patients only take once a week by injection under the skin
Global Pituitary Dwarf Treatment Market Scope
The pituitary dwarf treatment market is segmented on the basis of treatment, types, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Pituitary Dwarfism Type I
- Pituitary Dwarfism Type II
- Pituitary Dwarfism Type III
- Pituitary Dwarfism Type IV
- Others
Treatment
- Surgery
- Additional Therapy
- Drugs
- Others
Route of Administration
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Pituitary Dwarf Treatment Market Regional Analysis/Insights
The pituitary dwarf treatment market is analyzed and market size insights and trends are provided by treatment, type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the pituitary dwarf treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will be expecting positive growth for pituitary dwarf treatment market throughout the forecasted period due to the continuously increasing population resulting increasing prevalence of dwarfism and other growth hormone deficiency disorders.
North America dominates the market due to increased government awareness programs, advanced technology and treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Pituitary Dwarf Treatment Market Share Analysis
The pituitary dwarf treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pituitary dwarf treatment market.
Key players operating in the pituitary dwarf treatment market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Amneal Pharmaceuticals LLC. (U.S.)
- Elekta AB (Sweden)
- Alnylam Pharmaceuticals, Inc (U.S.)
- Apotex Inc (Canada)
- Armata Pharmaceuticals, Inc. (U.S.)
- Pfizer Inc (U.S.)
- H. Lundbeck A/S (Denmark)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
SKU-